Preterm birth (defined as birth before 37 completed gestational weeks), low birth weight (<2500 g) and small for gestational age (SGA) (birth weight below the 10th percentile for gestational age) are interrelated neonatal phenotypes that have lasting consequences for renal health. The source groups these phenotypes under the umbrella term small vulnerable newborn (SVN). Being born as an SVN ranks among the top risk factors for early mortality and establishes a lifelong susceptibility to chronic kidney disease (CKD). The article reports that approximately 35 million SVN are born globally each year, representing a substantial contribution to future CKD morbidity and mortality.
In SVN, nephron mass is reduced through two primary mechanisms described in the source: first, prematurity interrupts the normal process of nephrogenesis; second, an adverse intrauterine environment impairs nephron endowment. Together these processes result in fewer nephrons at birth. Reduced nephron number is central to the elevated lifetime risk for renal disease in this population.
The source outlines maladaptive hemodynamic and structural responses that follow low nephron mass. These include glomerular hyperfiltration, increased glomerular capillary pressure (glomerular hypertension) and progressive structural damage culminating in glomerular sclerosis. These compensatory and maladaptive changes drive progressive loss of renal function over time and increase the risk of CKD in survivors of prematurity and low birth weight.
Beyond the intrinsic deficit in nephron number, additional neonatal insults commonly encountered in the neonatal intensive care unit (NICU) further threaten renal outcome. The source identifies complications of prematurity that can cause renal hypoperfusion and notes that pharmacologic treatments used in neonatal intensive care can be nephrotoxic. These factors contribute to the occurrence of neonatal acute kidney injury (AKI) in SVN infants.
Neonatal AKI is described as common in this population and associated with high acute mortality. Importantly, the source frames neonatal AKI as a potentially modifiable “second hit” that accelerates the pathway from low nephron mass to CKD. This conceptualization highlights NICU-era events as targets for intervention to reduce long-term renal sequelae.
The source proposes a set of preventive strategies aimed at reducing SVN-related CKD risk. At the maternal and perinatal level, optimizing maternal health to prevent prematurity, low birth weight and SGA is recommended. During neonatal care, improved detection and avoidance of neonatal AKI are emphasized, specifically by reducing exposures that cause nephrotoxicity and by minimizing kidney hypoperfusion during NICU treatment. The authors also recommend systematic documentation of any neonatal AKI at discharge so that subsequent care teams are aware of the early renal insult.
The article recommends educating both physicians and families about the child’s lifelong CKD risk after SVN birth. Follow-up should be stratified on the basis of completed gestational weeks, birth weight, documented occurrence of neonatal AKI and coexisting comorbidities. The stated aims of follow-up are early identification and treatment of factors that drive CKD progression and of CKD complications, allowing earlier interventions to modify long-term outcomes.
The abstract highlights the epidemiologic scale of the problem and outlines key preventive and follow-up measures, but detailed operational guidance, specific screening intervals, thresholds for intervention, or data on the effectiveness of the listed strategies are not reported in the source abstract. Likewise, granular definitions of neonatal AKI diagnostics, the prevalence rates of AKI within SVN cohorts, and specific nephrotoxic agents implicated in NICU care are not provided in the abstract and therefore cannot be detailed here. Further reading of the full article would be required to access those specifics.
Summary
Prematurity, low birth weight and SGA—grouped as the small vulnerable newborn (SVN) phenotype—lead to reduced nephron mass and maladaptive renal responses that increase lifetime risk of CKD. Neonatal AKI, driven by hypoperfusion and nephrotoxic exposures during NICU care, is a frequent and potentially modifiable contributor to progression toward CKD. Preventive strategies include optimizing maternal health, avoiding neonatal kidney insults, documenting AKI at discharge, educating clinicians and families, and providing stratified follow-up to detect and manage CKD progression factors and complications.